National and International Guidelines for Overactive Bladder
- 396 Downloads
Overactive bladder (OAB) syndrome is an extremely prevalent and bothersome condition. Various providers from many fields, including primary care, geriatrics, neurology, gynecology, and urology, are involved in the diagnosis and management of a wide range of patients who present with symptoms of OAB. Several urologic, urogynecologic, geriatric societies and other organizations have developed guidelines for the evaluation and pharmacologic treatment of OAB. Guidelines are developed to facilitate the care of “index” patients by making recommendations based on grading the evidence in the current literature, with the goal of avoiding inconsistencies and biases. This chapter aims to review the current national and international guidelines on the evaluation and treatment of OAB. Generally, the guidelines agree with regard to recommendations for a basic initial evaluation with a limited role for invasive testing in the uncomplicated patient and conservative treatments for first-line therapy and pharmacotherapy as effective second-line therapy. There are slightly more heterogeneous recommendations for invasive therapies for OAB. This chapter reviews the recommendations relating to pharmacotherapy specifically.
KeywordsOveractive bladder Urgency Urgency urinary incontinence Urinary bladder Detrusor overactivity Guidelines
- 5.The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1979;121(9):1193–254.Google Scholar
- 6.OCEBM Levels of Evidence Working Group. The Oxford levels of evidence 2. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653. Accessed 19 June 2018.
- 7.Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (background document). Oxford Centre for Evidence-Based Medicine. https://www.cebm.net/index.aspx?o=5653 (2011). Accessed 19 June 2018.
- 8.Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ; American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. 2012; amended 2014. http://www.auanet.org/guidelines/overactive-bladder-(oab)-(aua/sufu-guideline-2012-amended-2014). Accessed 19 June 2018.
- 9.Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence. 6th ed. Bristol: ICI-ICS. International Continence Society; 2017.Google Scholar
- 10.National Institute for Health and Care Excellence. Urinary incontinence in women: the management of urinary incontinence in women. CG171. Published 2013; last updated 2015. http://www.ncbi.nlm.nih.gov/pubmed/25340217. Accessed 19 June 2018.
- 11.National Institute for Health and Care Excellence. Mirabegron for treating symptoms of overactive bladder. Technology appraisal guidance (TA290). Published 26 June 2013. https://www.nice.org.uk/guidance/ta290. Accessed 19 June 2018.
- 14.European Association of Urology. Guidelines. Gravas S, Cornu JN, Drake MJ, Gacci M, Gratzke C, Hermann TRW, et al. Treatment of Non-neurogenic Male LUTS. First published in 2000; updated in 2017. http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#1_4. Accessed 19 June 2018.
- 16.Geoffrion R; Urogynaecology Committee. Treatments for overactive bladder: focus on pharmacotherapy. J Obstet Gynaecol Can. 2012;34(11):1092–1101.Google Scholar
- 17.Tse V, King J, Dowling C, English S, Gray K, Millard R, et al. Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) guidelines on the management of adult non-neurogenic overactive bladder. Br J Urol. 2016;117(1):34–47.CrossRefGoogle Scholar
- 18.Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD, Shekelle P. Clinical guidelines Committee of the American College of Physicians. Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(10):429–40.CrossRefGoogle Scholar
- 20.Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2007;(4):CD003190.Google Scholar
- 21.Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;(4):CD003781.Google Scholar
- 22.Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011;(12):CD005493.Google Scholar